Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced that it is closing enrollment in its two phase 3 trials HZ-CA-301 and HZ-CA-303 for its lead product candidate HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be “GI-friendly”. “We enrolled over fifteen hundred patients in less than a year, which was well ahead of our projections,” said George F. Tidmarsh, M.D., Ph.D.

More: continued here

This entry was posted on Tuesday, February 12th, 2008 at 3:02 am and is filed under GastroIntestinal / Gastroentorology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.